Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Woman Dies 3 Days after COVID-19 Vaccine Shot, but Link Indeterminable
March 3, 2021
- MHLW Unveils List of “Stable Supply Medicines”
March 2, 2021
- Nichi-Iko to Get Business Suspension Order on March 3
March 2, 2021
- MHLW Study Group Compiles Guideline for Collecting COVID-19 Convalescent Plasma
March 2, 2021
- 172 Vials of Pfizer Vaccine Unusable due to Freezer Breakdown
March 2, 2021
- MHLW Asks Municipalities to Secure Adrenaline Preparations for Anaphylaxis
March 1, 2021
- PAFSC Minutes for Pfizer Vaccine Disclosed
March 1, 2021
- Govt to Deliver 1st COVID-19 Vaccine Dose for 3.7 Million HCPs in April: Minister
March 1, 2021
- MHLW Orders Label Revisions for NSAIDs, Salbutamol, Kymriah
March 1, 2021
- Japan Research Group to Wrap Up Report on Clinical Trials for Cannabis-Derived Drugs by March-End
February 26, 2021
- Key Panel Gives Thumbs-Up to Teijin’s Osteoporosis Med, JCR’s Hunter Syndrome Drug and More
February 26, 2021
- Japan Might Ease Temperature Requirements for Pfizer Vaccine
February 26, 2021
- MHLW Panel Shelves Decision on Bayer’s Heart Failure Med Vericiguat
February 26, 2021
- CSL Plans Export of 2 Surplus Human Immunoglobulin Products
February 26, 2021
- 17,888 Doses of COVID-19 Vaccine Given in Japan as of Feb. 24
February 25, 2021
- Nichi-Iko Likely to Face Biz Suspension Order over Spate of Recalls
February 25, 2021
- MHLW Approves Add’l Use for Thaled, Bavencio and More
February 25, 2021
- 10,000 COVID-19 Patients Received Avigan in Observational Studies: Govt
February 25, 2021
- MHLW Formally Adopts GS1 Codes for Electronic Package Inserts; Rule to Take Effect August 1
February 25, 2021
- Japan to Start Elderly Vaccine Rollout from April 12: Minister
February 25, 2021
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…